fluorodeoxyglucose f18 has been researched along with Smoldering Multiple Myeloma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Landgren, CO; Ulaner, GA | 1 |
| Choyke, P; Dew, A; Hill, E; Kazandjian, D; Lindenberg, L; Mena, E; Morrison, C | 1 |
1 review(s) available for fluorodeoxyglucose f18 and Smoldering Multiple Myeloma
| Article | Year |
|---|---|
Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders.
Topics: ADP-ribosyl Cyclase 1; B-Cell Maturation Antigen; Biomarkers, Tumor; Bone Marrow; Disease Progression; Fluorodeoxyglucose F18; Gene Expression; Humans; Membrane Glycoproteins; Neoplasm Proteins; Neoplasm, Residual; Plasma Cells; Plasmacytoma; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Receptors, CXCR4; Smoldering Multiple Myeloma | 2020 |
1 other study(ies) available for fluorodeoxyglucose f18 and Smoldering Multiple Myeloma
| Article | Year |
|---|---|
Diagnostic performance of
Topics: Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Multiple Myeloma; Osteolysis; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Radiography; Reproducibility of Results; Sensitivity and Specificity; Smoldering Multiple Myeloma | 2021 |